NEW YORK—Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced two research presentations that will be featured at the 2026 Special Operations Medical Association (SOMA) Scientific Assembly April 27-May 1 in Raleigh, North Carolina, highlighting the real-world use of TRAUMAGEL® in prehospital trauma care settings.
These presentations include a podium session evaluating the use of TRAUMAGEL as a hemostatic adjunct in prehospital trauma care, as well as a case report demonstrating its use in a complex extremity injury.
Podium Presentation Details
Title: Operational Evaluation of a Novel Flowable Hemostatic Adjunct in Prehospital Trauma: A 17 Case Initial Review
Presenter: David J. Kleiman, Cobb County Fire & Emergency Services, Marietta, Georgia
Date and Time: Wednesday, April 29, 4:20-4:30 p.m. ET
This presentation reports findings from a retrospective case series evaluating the use of TRAUMAGEL as a hemostatic adjunct in prehospital trauma care. The analysis examines EMS provider use across 17 cases, including time to bleeding control, durability of hemostasis during transport and overall effectiveness in prehospital hemorrhage control.
Poster Presentation Details
Title: Prehospital Emergency Response in a Partial Hand Amputation with Ulnar Artery Transection: A Case Report
Presenter: Jeffrey Elian, Orangeburg County Emergency Medical Services, Orangeburg, South Carolina
Date and Time: Tuesday, April 28, 6:30-7:30 p.m. ET
This case report describes the prehospital management of a partial hand amputation involving ulnar artery transection. TRAUMAGEL was used as a hemostatic adjunct following initial tourniquet application, enabling bleeding control and tourniquet removal during prolonged transport. The case highlights its potential role in prehospital hemorrhage control while mitigating ischemic risk prior to definitive surgical care.
Cresilon representatives will be available during the conference to discuss the clinical application and deployment of TRAUMAGEL in emergency response and trauma care settings. A copy of the poster presentation will be available online after the conclusion of the event at https://cresilon.com/traumagel/.
The SOMA Scientific Assembly is the association’s annual meeting, bringing together military and civilian medical professionals to share best practices, research and innovation in tactical, prehospital and austere medicine. The meeting includes participants from U.S. and international military, law enforcement and emergency medical services, and focuses on advancing care in high-threat and resource-limited environments.
About Cresilon
Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures and markets hemostatic medical devices utilizing the company’s proprietary hydrogel technology. The company’s plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company’s current and future product lines target trauma care, biosurgery and animal health. Cresilon’s mission is to save lives. The company was recognized by Fast Company as one of the World’s 50 Most Innovative Companies and named an EMS World Innovation Awards winner for TRAUMAGEL. For more information about Cresilon, visit www.cresilon.com.
Media Contact
STiR Communications
Gregory Salsburg
greg@stir-communications.com